Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.

The Journal of clinical endocrinology and metabolism - 1 Feb 2017

Wang Weibin, Kang Helen, Zhao Yinu, Min Irene, Wyrwas Brian, Moore Maureen, Teng Lisong, Zarnegar Rasa, Jiang Xuejun, Fahey Thomas J

Abstract excerpt

Context: The RAF inhibitor vemurafenib has provided a major advance for the treatment of patients with BRAF-mutant metastatic melanoma. However, BRAF-mutant thyroid cancer is relatively resistant to vemurafenib, and the reason for this disparity remains unclear. Anticancer therapy-induced autophagy can trigger adaptive drug resistance in a variety of cancer types and treatments. To date, role of autophagy during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Endoplasmic Reticulum Stress

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Mice, SCID

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 27754804
DOI: 10.1210/jc.2016-1999
PMCID: PMC5413163

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.PMID 27754804Read ↗

Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.Semantic proximity Read ↗

BRAF V600E-dependent role of autophagy in uveal melanoma.Semantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies.Semantic proximity Read ↗

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.Semantic proximity Read ↗

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.Semantic proximity Read ↗

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Semantic proximity Read ↗

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.Semantic proximity Read ↗

Autophagy sustains mitochondrial respiration and determines resistance to BRAF V600E inhibition in thyroid carcinoma cellsSemantic proximity Read ↗

V600EBRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Synergistic Effect of Metformin and Vemurufenib (PLX4032) as a Molecular Targeted Therapy in Anaplastic Thyroid Cancer – An In Vitro StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.